Technetium-99m depreotide imaging by single photon emission tomography/low resolution computed tomography in malignant lymphomas: Comparison with gallium-67 citrate

Annals of Nuclear Medicine

Volumn 24, Issue 9, 2010, Pages 639-647

  Apostolopoulos, Dimitris J ^a   Papandrianos, Nikolaos I ^a   Symeonidis, Argiris ^b   Spyridonidis, Tryfon ^a   Alexiou, Sotiria ^a   Zampakis, Petros ^b   Savvopoulos, Christos ^a   Vassilakos, Pavlos J ^a   Matsouka, Panagiota ^b  

^a UNIVERSITY OF PATRAS   (Greece)

^b UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

Comparison; Ga 67 citrate; Lymphoma imaging; SPECT CT; Tc 99m depreotide

Indexed keywords

CITRIC ACID; DEPREOTIDE TC 99M; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GALLIUM; GALLIUM CITRATE; SOMATOSTATIN; TECHNETIUM COMPLEX;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LYMPH NODE; LYMPHOMA; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSPORT AT THE CELLULAR LEVEL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CITRATES; FEMALE; GALLIUM; HUMANS; LYMPH NODES; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOTECHNETIUM COMPOUNDS; RECURRENCE; SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 79953235366     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-010-0405-7     Document Type: Article

References (27)

1. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S42-55. (Pubitemid 36735762)
2. Even-Sapir E, Israel O. Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S65-81. (Pubitemid 36735764)
3. Palumbo B, Sivolella S, Palumbo I, Liberati AM, Palumbo R. 67 Ga-SPECT/CT with a hybrid system in the clinical management of lymphoma. Eur J Nucl Med Mol Imaging. 2005;32:1011-7. (Pubitemid 41339275)
4. Kostakoglu L, Goldsmith SJ. Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography. Clin Lymphoma. 2000;1:67-74.
5. Barrington SF, O'Doherty MJ. Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(Suppl 1):S117-27. (Pubitemid 36735769)
6. Ferone D, Semino C, Boschetti M, Cascini GL, Minuto F, Lastoria S. Initial staging of lymphoma with octreotide and other receptor imaging agents. Semin Nucl Med. 2005;35:176-85. (Pubitemid 41138136)
7. Leners N, Jamar F, Fiasse R, Ferrant A, Pauwels S. Indium- 111-Pentetreotide Uptake in Endocrine Tumors and Lymphoma. J Nucl Med. 1996;37:916-22. (Pubitemid 126447121)
8. Sarda L, Duet M, Zini JM, Berolatti B, Benelhadj S, Tobelem G, et al. Indium-111 pentetreotide scintigraphy in malignant lymphomas. Eur J Nucl Med. 1995;22:1105-9.
9. Lipp RW, Silly H, Ranner G, Dobnig H, Passath A, Leb G, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy. J Nucl Med. 1995;36:13-8.
10. Ivancević V, Wörmann B, Nauck C, Sandrock D, Munz DL, Hiddemann W, et al. Somatostatin receptor scintigraphy in the staging of lymphomas. Leuk Lymphoma. 1997;26:107-14. (Pubitemid 27351013)
11. Lugtenburg PJ, Löwenberg B, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. J Nucl Med. 2001;42:222-9. (Pubitemid 32150512)
12. Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron-emission tomography. Horm Metab Res Suppl. 1993;27:56-8. (Pubitemid 23132620)
13. Virgolini I, Leimer M, Handmaker H, Lastoria S, Bischof C, Muto P, et al. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998;58:1850-9. (Pubitemid 28217458)
14. Raderer M, Valencak J, Pfeffel F, Drach J, Pangerl T, Kurtaran A, et al. Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type. J Natl Cancer Inst. 1999;91:716-8. (Pubitemid 29234566)
15. Dalm VASH, Hofland LJ, Mooy CM, Waaijers MA, van Koetsveld PM, Langerak AW, et al. Somatostatin receptors in malignant lymphomas: targets for radiotherapy? J Nucl Med. 2004;45:8-16. (Pubitemid 47611602)
16. Cholewinski W, Kowalczyk JR, Stefaniak B, Stefaniak J, Poniatowicz-Frasunek E, Tarkowska A. Diagnosis and staging of children's lymphoma using the technetium-labelled somatostatin analogue, 99mTc-depreotide. Eur J Nucl Med Mol Imaging. 2004;31:820-4. (Pubitemid 38758351)
17. Bushnell DL, Menda Y, Madsen MT, Link BK, Kahn D, Truhlar SM, et al. 99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma. Nucl Med Commun. 2004;25:839-43. (Pubitemid 39099998)
18. Montilla-Soler JL, Rexroad JT, Bridwell RS. Tc-99m depreotide scintigraphy of low-grade non-Hodgkin's lymphoma. Clin Nucl Med. 2003;28:503-5. (Pubitemid 38295232)
19. Danielsson R, Bååth M, Kölbeck K-G, Klominek J, Svensson L. Accumulation of Tc-99m depreotide (NeoSpect) in axillary sweat glands. Clin Nucl Med. 2003;28:789-90. (Pubitemid 38295216)
20. Lugtenburg PJ, Krenning EP, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, et al. Somatostatin receptor scintigraphy useful in stage I-II Hodgkin's disease: more extended disease identified. Br J Haematol. 2001;112:936-44. (Pubitemid 32322918)
21. Lastoria S, Palmieri G, Muto P, Lombardi G. Functional imaging of thymic disorders. Ann Med. 1999;31(Suppl 2):63-9. (Pubitemid 29497709)
22. Reubi JC, Waser B, van Hagen M, Lamberts SWJ. In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer. 1992;50:895-900.
23. Karam M, Novak L, Cyriac J, Ali A, Nazeer T, Nugent F. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175-83. (Pubitemid 43939045)
24. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25-30.
25. Raderer M, Traub T, Formanek M, Virgolini I, Osterreicher C, Fiebiger W, et al. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type. Br J Cancer. 2001;85:1462-6. (Pubitemid 34001574)
26. Landgren O, Tilly H. Epidemiology, pathology and treatment of non-follicular indolent lymphomas. Leuk Lymphoma. 2008;49(Suppl 1):35-42.
27. Mazloom A, Medeiros LJ, McLaughlin PW, Reed V, Cabanillas FF, Fayad LE, et al. Marginal zone lymphomas: factors that affect the final outcome. Cancer 2010 [Epub ahead of print].